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http://dx.doi.org/10.1016/j.pedneo.2Background: Non-viral limbic encephalitis, which may be paraneoplastic or idiopathic, is in-
creasingly recognized in adults and children. Early identification of potential patients, who
have neuronal autoantibodies to intracellular or neuronal surface antigens in order to give ap-
propriate immunotherapy, is key to improving the prognosis. This cross-sectional study de-
scribes the clinical manifestation and the serological evidence of the presence of neuronal
antibodies in Taiwanese children with limbic encephalitis.
Method: We enrolled children and adolescents who had been hospitalized due to nonviral
limbic encephalitis. Serum samples from these patients were collected to screen antibodies
against intracellular antigens [amphiphysin, Ma2, Ri, Yo, Hu and antiglutamic acid decar-
boxylase (GAD)] and neuronal surface antigens [N-methyl-D-aspartate (NMDA) receptor, g-
amino butyric acid (GABAB) receptor and voltage-gated potassium channel complexes
(VGKCs)].Pediatric Neurology, Chang Gung Memorial Hospital and Chang Gung Children’s Hospital, #5 Fu-Shin
an.
.org.tw (K-L. Lin).
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Limbic encephalitis in Taiwanese children 247Results: All of the 10 enrolled patients had acute onset of fever and rapid clinical deteriora-
tion. They had persistent neuropsychiatric symptoms and 90% developed refractory epi-
lepsy, despite six patients having been treated with methylprednisolone pulse therapy or
intravenous immunoglobulin (IVIG) at the acute stage. In the laboratory findings, half of
the cases were positive for antibodies with regards to intracellular antigens (amphiphysin
or GAD). The general outcomes, assessed by Glasgow Outcome Scale, were similar between
patients with and those without the antibodies (Mann-Whitney U test, p Z 0.43). One pa-
tient, who was positive for antibodies to amphiphysin 10 years after disease onset, still
had a significant response to oral prednisolone therapy. At the end of the follow-up period,
no cancer or insulin-dependent diabetes mellitus was detected in any of the patients.
Conclusion: This study provides evidence for a potential association between antibodies
and limbic encephalitis. The presence of antibodies, especially antibodies to GAD, may
serve as an indicator for immunotherapy.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Limbic encephalitis refers to non-viral inflammation,
mainly involving the limbic system, including the medi-
otemporal lobes, amygdala, and cingulate gyrus. It is
defined by clinical symptoms, such as retrograde amnesia,
temporal lobe seizures, or psychiatric symptoms, and by
radiological evidence, such as nonatrophic hyperintensity
of the mediotemporal lobes at early course, or by detection
of antibodies associated with limbic encephalitis.1e6 The
relevant antibodies are directed against two categories of
neuronal antigens: (1) intracellular antigens, including
classic onconeuronal antigens (amphiphysin, Ma2, Ri, Yo,
and Hu) and other antigens [glutamic acid decarboxylase
(GAD)]4,7e9; (2) neuronal surface antigens, including sur-
face ion channels or receptors and proteins adjacent or
linked to such channels or receptors [N-methyl-D-aspartate
(NMDA) receptor, g-amino butyric acid-B (GABAB) receptor,
voltage-gated potassium channel complexes (VGKCs)].10e14
Currently, limbic encephalitis can be classified as para-
neoplastic or idiopathic (non-paraneoplastic). Patients are
given the former diagnosis if there is a reactivity of the
antibodies to antigens in both brain and tumor tissues and
the latter in the absence of such an associated
malignancy.15,16
The role of these antibodies in limbic encephalitis has
not yet been clearly understood. Antibodies to most intra-
cellular onconeuronal antigens are not thought to be
pathogenic for limbic encephalitis, but are useful clinical
biomarkers for occult neoplasm.9,17 However, recent his-
topathological studies from brain biopsies in adults, sug-
gested a central role for T cell-mediated neuronal
cytotoxicity in encephalitides associated with antibodies
against intracellular antigens.18 The neurological outcome
is usually poor, although stabilization has been observed
after tumor treatment.19 In contrast, antibodies against the
majority of surface antigens are supposedly pathogenic
through an antibody- and complement-mediated immune
response.13,18 Idiopathic cases generally fall in to this sub-
group and have a better outcome.19 Furthermore, the titer
of antibodies against intracellular antigens may not corre-
late well to treatment outcome; by contrast, the titer ofantibodies to some surface antigens, such as VGKCs, can
reflect the efficacy of immunotherapy.7
Since the reports of cases of paraneoplastic limbic en-
cephalitis in the 1960s,20 the awareness and interest of
limbic encephalitis, associated with malignancy or not,
have increased not only in adults, but also in children and
adolescents.4,17,18,21,22 However, the value of antibodies in
children with idiopathic limbic encephalitis has only been
evaluated in the European multicenter study, where eight
out of 10 children (aged 3e17 years) were found to have
antibodies against neuronal proteins (1 Hu, 1 Ma2, 2 GAD, 2
VGKC, and 2 VGKC plus GAD).4 In our clinical experience,
limbic encephalitis is often preceded by fever and the pa-
tient’s condition deteriorates despite aggressive treat-
ment.23,24 To identify the patients who have neuronal
antibodies to intracellular or neuronal surface antigens, in
order to give early immunotherapy, is beneficial for the
prognosis. This cross-sectional study describes the clinical
manifestation and the serological evidence of the presence
of neuronal antibodies in Taiwanese children and adoles-
cents with idiopathic limbic encephalitis.
2. Methods
2.1. Patients
This study was approved by the Institutional Review Board
of the Chang Gung Memorial Hospital (IRB 99-0260B). The
present study included patients with a history of limbic
encephalitis in a single tertiary centre in Taiwan. Consent
was obtained and blood sample collections were conducted
between September 2010 and March 2011. The inclusion
criteria were as follows: (1) previously healthy children
with acute-onset intractable seizures, plus one other fea-
ture of limbic encephalitis (consciousness disturbances,
hallucination, and memory impairment) who were hospi-
talized during the acute stage; (2) negative results of
microbiology workup, including bacterial and viral culture,
polymerase chain reaction (PCR), and serology; (3) the
presence of abnormality in the mediotemporal area, as
revealed by fluid-attenuated inversion recovery sequence
248 I-J. Chou et al(FLAIR) imaging in magnetic resonance imaging (MRI); and
(4) age of onset <18 years. The exclusion criteria were:
a history of unprovoked or febrile seizures, developmental
delay or intelligence deficit, prior neurologic insult, pro-
gressive neurologic disorder, congenital central nervous
system malformation evident on neuroimaging, inborn error
of metabolism, connective tissue disease, electrolyte
imbalance, and hypoglycemia (Figure 1).
An extensive chart review was conducted by a pediatric
neurologist, based on the following aspects: baseline
characteristics; details of the clinical course; findings of
laboratory tests, imaging studies, and neurological and
psychiatric evaluations; and outcomes. Each patient was
re-examined by two independent pediatric neurologists.
Disagreements in their opinions were resolved by a third
pediatric neurologist.
The determination of outcome was based on the findings
of the latest patient assessment before April 1, 2012. The
patients were assessed using the Glasgow Outcome Scale
(GOS). The GOS has been described previously in detail.25 In
brief, a GOS score of 1 indicates death, 2 indicates chronic
vegetative state, 3 indicates disability that is severe
enough to preclude living independently, 4 indicates mod-
erate disability causing difficulty in returning to social ac-
tivities despite an independent daily life, and 5 indicates
good recovery with mild or no disability.
2.2. Antibodies to intraneuronal antigens:
Onconeuronal and anti-GAD antibodies
Euroline antineuronal autoantibody profile (Euroimmun,
Lu¨beck, Germany) consisting of a membrane strip with theFigure 1 The mediotemporal areas in patient 6 showed
hyperintensity, as revealed by fluid-attenuated inversion re-
covery sequence (FLAIR) imaging.five onconeuronal autoantigens, namely, amphiphysin,
Ma2, Ri, Yo, and Hu, was used. According to the manufac-
turer’s instructions, diluted patient samples (1:100) were
incubated with the immunoblot strips. In positive cases, the
specific IgG binds to the corresponding antigenic site. To
detect the bound antibodies, a second incubation was
carried out using an enzyme-labeled antihuman IgG
(enzyme conjugate) that catalyses a color reaction. The
results were digitally interpreted using EUROLineScan and
were scored as negative, borderline, or positive.
Antibodies to GAD were screened by enzyme-linked
immunosorbent assay (ELISA) (RSR Ltd, Cardiff, UK). A
value 5 units/mL was interpreted as a positive result. The
presence of antibodies to GAD was also tested by indirect
immunofluorescence performed on cryosections of
adult rhesus monkey cerebellum, using a fluorescein
isothiocyanate-labeled technique (Euroimmun).
2.3. Antibodies to neuronal surface antigens: Anti-
NMDA, anti-GABABB, and anti-VGKC antibodies
The presence of antibodies to neuronal surface antigens,
including glutamate receptors [type NMDA, type alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
1 and type AMPA 2], VGKCs [contactin-associated protein
2(Caspr2) and leucine-rich glioma-inactivated protein
1(Lgi1)], and GABA receptor B1, were screened by immuno-
fluorescence on human embryonic kidney (HEK)-293 cells
transfected with plasmids containing the appropriate anti-
gens (Euroimmun). Antibodies to VGKCs were also tested by
radioimmunoassay (RSR Ltd) and considered positive with
a titer >100 pmol/L.
2.4. Antibodies to other antigens: ANA and Anti-
ENA antibodies
Antinuclear antibodies (ANA) with HEp-2 cells as substrate
(Immuno Concepts, Sacramento, CA, USA) were tested as
previously described.26 ELISA was used for specific testing
of anti-extractable nuclear antigens (anti-ENA), including
Sm, RNP, SSA/Ro, SSB/La, Scl 70, Jo 1, double-stranded DNA
(dsDNA) autoantibodies, Cent B, and histone (Pharmacia
Diagnostics, Freiburg, Germany).
2.5. Statistical analysis
Summary statistics were expressed as mean  standard
deviation for continuous variables. The clinical character-
istics, management and outcomes of patients, with or
without antibodies, were compared by the Mann-Whitney U
test for continuous variables and the Fisher’s exact test for
categorical data. All analyses were performed using SPSS
version 17 (SPSS Inc, Chicago, IL, USA). A p value <0.05 was
considered to be statistically significant. All statistical tests
were two-tailed.
3. Results
In all, 10 patients (6 boys and 4 girls) were enrolled. The
average age of onset was 10.5 years (rangeZ 2e16 years).
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clinical deterioration were noted in all patients, and seven
patients developed respiratory failure and consciousness
disturbance with Glasgow Coma Scale (GCS) <8, therefore
endotracheal intubation and mechanical ventilation were
necessary. Patient characteristics, treatment modalities,
and outcomes are shown in Table 1.
The mean follow-up duration was 5.6 years
(range Z 1.5e11 years). At the end of the study, all pa-
tients had neuropsychiatric symptoms and 90% of the pa-
tients continued to have refractory epilepsy, even after
being discharged from hospital. During the study period,
malignancy and insulin-dependent diabetes mellitus (IDDM)
were not detected in any of the patients.3.1. Autoantibody status
Serum samples were collected at 3 days to 10 years after
the onset of limbic encephalitis, and were positive for
antibodies to intracellular antigens, amphiphysin or GAD,
in 50% of the cases (Table 2). Of the 10 patients, three
(30%) were positive for antibodies to amphiphysin (pa-
tients 1, 2 and 3). Antibodies to GAD were found in three
(30%), with antibody concentrations of 63.17, 45.06, and
16.52 IU/mL for patients 3, 4 and 9, respectively. In
particular, patient 3 had both antibodies to amphiphysin
and GAD (63.17 IU/mL). Of the five patients who under-
went ANA studies, only a low titer was detected in three
serum samples. Antibodies against neuronal surface an-
tigens and ENA yielded negative results in all tested
patients.3.2. Autoantibody and clinical outcomes
The general outcomes, assessed by GOS, were similar in
patients with and those without the antibodies (p Z 0.43)
(Table 3).The GOS scores were 3 in 40% (2/5), 4 in 20% (1/
5), and 5 in 40% (2/5) of the patients with antibodies to
amphiphysin or GAD.
Neuropsychiatric symptoms, poor memory, and temporal
lobe seizures remained as the major problems in those who
can attend schools (GOS 5). Follow-up MRI scans were
performed in seven patients, and mesiotemporal sclerosis
was noted in six patients, including patient 2 (with anti-
bodies to amphiphysin) and patient 4 (with antibodies to
GAD).3.3. Immunotherapy
Besides anticonvulsants and supportive care,23 immuno-
therapy was administered at the acute stage (<1 month
after disease onset). Two patients received intravenous
immunoglobulin G (IVIG), while four received combined
IVIG and methylprednisolone pulse therapy (30 mg/kg/dose
once daily for 3 days). At the chronic stage, patient 2
received oral prednisolone therapy after serum anti-
amphiphysin antibodies were detected (10 years after dis-
ease onset), and the symptoms, including seizures and
hallucinations, subsequently disappeared.4. Discussion
This study reported a group of children and adolescents
with acute limbic encephalitis who showed clinical features
of fever and rapid clinical deterioration at the acute stage,
followed by refractory epilepsy with a spectrum of neuro-
psychiatric presentations. We use comprehensive and up-
to-date techniques to determine widely acknowledged
antibody reactivity. In half of the cases, serum samples
were positive for antibodies to intracellular antigens
(amphiphysin or GAD). Although the association between
the aforementioned antibodies and paraneoplastic syn-
drome has been reported, none of our patients developed
neoplasm during the follow-up period.8,27
Two case series involving children and adolescents with
idiopathic limbic encephalitis have been reported; one
focused on subacute limbic encephalitis in Europe and the
other focused on acute limbic encephalitis in Japan.4,21 The
European case series reported female predominance (90%);
in contrast, the Japanese series (female: 43%) and our
study (female: 40%) showed a slightly higher male pre-
dominance. In a majority of the cases in the Japanese se-
ries (8/14) and all in our series (10/10), febrile illness
preceded the acute onset of seizures and impaired con-
sciousness. The clinical outcomes were all unfavorable, and
the incidence of refractory epilepsy after the acute stage
was very high (90%) in our study.
The association between antibodies to GAD and idio-
pathic limbic encephalitis has been reported in both adults
and children.4,7,8,28 GAD catalyzes the synthesis of GABA,
the major inhibitory neurotransmitter in the central ner-
vous system. A recent histopathological study provided
evidence of T-cell mediated inflammation in limbic en-
cephalitis with antibodies to GAD.18 In adults, a recent
study suggested that the incidence of refractory epilepsy
was higher among limbic encephalitis cases with antibodies
to GAD, than those with antibodies to VGKCs.7 In addition,
a serum level >1000 U/mL was perhaps more relevant to
limbic encephalitis, in contrast with those with IDDM.8 In
children and adolescents, high titers of anti-GAD antibodies
have also been detected in 40% of cases of subacute idio-
pathic limbic encephalitis.4 Our study found a 30% positive
rate of anti-GAD antibody, but with low titers. Fur-
thermore, cases with antibodies to GAD have a severe
neurological condition and no IDDM, notwithstanding low
serum titers. We also conducted the serological tests in
a cohort of encephalitis and therapy resistant epilepsy
patients.29,30 The value of low titer of antibodies to GAD
has been assessed in our recent report, where it was more
likely to be detected in patients with encephalitis, includ-
ing limbic encephalitis, than therapy-resistant epilepsy
without preceding encephalitis.30
Antibodies to amphiphysin have also been reported in an
adult with idiopathic limbic encephalitis, but clinical de-
tails were not available.7 Amphiphysin plays a role in syn-
aptic endocytosis and amphiphysin-knockout mice were
noted to have irreversible seizures.31 However, the clinical
and histopathological report on antibodies to amphiphysin
in idiopathic limbic encephalitis is scarce; the association
between antibodies to amphiphysin and idiopathic limbic
encephalitis needs to be carefully evaluated in the future.
Table 1 The clinical characteristics, treatments, and outcomes of 10 patients having acute limbic encephalitis followed by refractory epilepsy.
Case Onset Acute stage Latency Outcome
Age/gender Fever Preceding s/s CSF (WBC, per
mL, protein)
Intractable
seizures/ AEDs
ETT Hypotension IVMP IVIG s/s onset
to test
Disease
duration
MTS RE GOS Psychiatric outcomes
1 12 y/M ＋ URI WBC 5, p - (þ)/6 ＋    4 y 5 y  ＋ 3 MR
2 13 y/F ＋ URI WBC 1, p - (þ)/3     10 y 11 y ＋ ＋ 5 Hallucination
3 12 y/M ＋ Lethargy WBC 3 (þ)/7 ＋ ＋ ＋ ＋ 2 mo 2 y  ＋ 3 MR, behavioral
change, dysphagia
4 8 y/M ＋ Vesicle on upper
lip
WBC 10 (þ)/4 ＋    10 y 11 y ＋ ＋ 4 Behavioral change,
suicidal tendency
5 11 y/M ＋ URI WBC 7, p - (þ)/6 ＋  ＋ ＋ 5 mo 3 y ＋ ＋ 4 Violence, suicidal
tendency, aphasia
6 16 y/F ＋ URI WBC 4, p - (þ)/7 ＋  ＋ ＋ 1 y 2 mo 3 y ＋ ＋ 3 MR, ataxia
7 14 y/F ＋ URI WBC 0, p - (þ)/6 ＋   ＋ 4 y 6 y ＋ ＋ 3 MR
8 11 y/M ＋ Vomiting,
headache
WBC 1, p - (þ)/3    ＋ 1 y 6 mo 3 y 6 mo ＋ ＋ 4 Memory regression
9 2 y/M ＋ Vomiting WBC 6, p - (þ)/3 ＋  ＋ ＋ 3 d 1 y 6 mo   5 Hyperactivity
10 6 y/F ＋ diarrhea, neck
Lymphadenopathy
WBC 1, p - (þ)/3     9 y 10 y  ＋ 5 Hallucination,
tantrum
AEDs Z types of anticonvulsants; CSF Z cerebrospinal fluid; ETT Z endotracheal tube; F Z Female, GOS Z Glasgow outcome scale; IVMP Z intravenous methylprednisolone pulse
therapy (30 mg/kg/dose once daily for 3 days); IVIGZ intravenous immunoglobulin G; MZ male; MRZ mental retardation; MTSZ mesiotemporal sclerosis; pZ protein <45 mg/dL; s/
s Z symptoms and signs; RE Z refractory epilepsy; URI Z upper respiratory tract infection; WBC Z white blood cell.
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Table 3 Clinical presentations, management, and out-
comes in limbic encephalitis patients with or without
autoantibodies.
Abþ (n Z 5) Ab- (n Z 5) p
Age at onset (y) 9.4  4.6 9.6  3.5 1.000
Gender
Male 4 2 1.000
Female 1 3
Acute stage
CSF white blood cell
count (cells/uL)
5.0  3.4 2.6  2.9 0.389
ETT due to GCS <8 4 3 1.000
Hypotension 1 0
Types of AEDs for
intractable
seizures
4.6  1.8 5.0  1.9 0.524
Immunotherapy
(n Z 6)
2 4 1.000
IVIG 0 2
Combine IVIG
and IVMP
2 2
Latency (s/s onset
to test)
<3 mo 2 0 0.834
3 mo, 5 y 1 4
>5 y 2 1
Outcomes
Glasgow Outcome
Scale score
4.0  1.0 3.8  0.8 0.432
Refractory epilepsy 5 4
MRI follow up
(n Z 7)
3 4
Mesiotemporal
sclerosis
2 4
Communicating
hydrocephalus
1 1
Cerebral atrophy 0 2
AbZautoantibodies;AEDZanticonvulsants;CSFZcerebrospinal
fluid; ETT Z endotracheal tube; GCS Z Glasgow Coma Scale;
IVIGZ intravenous immunoglobulin; IVMPZ intravenous methyl-
prednisolone; MRIZmagnetic resonance image; s/sZ symptoms
and signs.
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is suspected, and a continuing search of associated neo-
plasm, have been suggested.32 There is as yet no stan-
dardized immunotherapy strategy available, but many
authors consider high-dose steroids and IVIG as first-line
management.4,33 An associated tumor diagnosis is usually
within 5 years from onset of limbic encephalitis symptoms
and tumor resection is beneficial to stop deterioration of
neurological symptoms.33 Although 60% of our patients
were treated with methylprednisolone pulse therapy or
IVIG at the acute stage, all of them still had neuro-
psychiatric symptoms and 90% developed refractory epi-
lepsy. Since only a limited number of cases were examined
here, discussing the effects of immunomodulatory therapy
was difficult. The encouraging result from this study is that
one patient, who was positive for antibodies to
252 I-J. Chou et alamphiphysin 10 years after disease onset, still had a signif-
icant response to oral prednisolone therapy.
A number of limitations regarding this study merit dis-
cussion. First, we used a semi-quantitative approach to
detect antibodies to amphiphysin. Therefore, the precise
serum levels of antibodies to amphiphysin could not be
determined. Second, we cannot exclude the possibility of
selection bias by enrolling more complicated cases,
because these cases came from a tertiary teaching hospi-
tal. Third, we did not perform tests for antineuronal anti-
bodies and oligoclonal bands in cerebrospinal fluid, as
intrathecal synthesis of antibodies may supplement infor-
mation for immunological repertoire. Furthermore, we
cannot account for variations in the serum levels of auto-
antibodies across time, mainly due to the retrospective
nature of this study.
5. Conclusion
This study yielded an insight into the potential association
between antibodies and non-viral limbic encephalitis with
refractory epilepsy. The presence of antibodies, especially
anti-GAD, may serve as an indicator for immunotherapy
among limbic encephalitis patients. Thus, further study is
needed to confirm our findings.
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